Prescription based, and already pre-approved by insurance companies to cover the costs at these prices.
For cosmetic reasons is the only reason a person will have to pay out of pocket, and these people are never accounted for in company figures and will be yet another wildcard to add to the overall sales figure one day.
BOT is a goldmine in the making for us early holders...and its still early for those on the fence, like not even on the starting block for what's to come.
Good luck on the 20th holders, it's going to be a blast
Sofdra US Sales Curve, page-6
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.0¢ | $1.603M | 4.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 378157 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 98000 | 5 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |